Ensign Peak Advisors Inc Buys 1,450 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)

Ensign Peak Advisors Inc lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) by 9.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 17,240 shares of the biopharmaceutical company’s stock after purchasing an additional 1,450 shares during the period. Ensign Peak Advisors Inc’s holdings in PTC Therapeutics were worth $865,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in PTCT. Altshuler Shaham Ltd purchased a new stake in PTC Therapeutics during the 3rd quarter valued at $25,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of PTC Therapeutics in the third quarter worth approximately $34,000. Focused Wealth Management Inc bought a new stake in shares of PTC Therapeutics in the third quarter worth approximately $60,000. Nisa Investment Advisors LLC grew its stake in shares of PTC Therapeutics by 26.0% in the third quarter. Nisa Investment Advisors LLC now owns 2,514 shares of the biopharmaceutical company’s stock worth $99,000 after acquiring an additional 518 shares during the period. Finally, Shell Asset Management Co. grew its stake in shares of PTC Therapeutics by 87.1% in the second quarter. Shell Asset Management Co. now owns 2,925 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 1,362 shares during the period.

Insider Buying and Selling at PTC Therapeutics

In other news, CEO Stuart Walter Peltz sold 1,786 shares of the company’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $41.66, for a total transaction of $74,404.76. Following the transaction, the chief executive officer now owns 171,699 shares in the company, valued at $7,152,980.34. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Stuart Walter Peltz sold 1,786 shares of the firm’s stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $41.66, for a total transaction of $74,404.76. Following the sale, the chief executive officer now owns 171,699 shares of the company’s stock, valued at approximately $7,152,980.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Neil Gregory Almstead sold 716 shares of the firm’s stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $41.66, for a total transaction of $29,828.56. Following the sale, the insider now directly owns 65,435 shares in the company, valued at approximately $2,726,022.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,951 shares of company stock valued at $700,923. 6.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

PTCT has been the topic of a number of research reports. Raymond James dropped their price objective on shares of PTC Therapeutics from $60.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, February 23rd. Morgan Stanley boosted their target price on shares of PTC Therapeutics from $40.00 to $50.00 and gave the stock an “equal weight” rating in a report on Friday, February 3rd. Cantor Fitzgerald reduced their price target on shares of PTC Therapeutics from $68.00 to $66.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 22nd. The Goldman Sachs Group started coverage on shares of PTC Therapeutics in a research report on Wednesday, December 14th. They issued a “sell” rating and a $35.00 price target on the stock. Finally, Royal Bank of Canada boosted their price objective on shares of PTC Therapeutics from $44.00 to $51.00 in a research report on Wednesday, February 22nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $52.80.

PTC Therapeutics Price Performance

PTCT stock opened at $44.23 on Monday. The firm has a 50-day simple moving average of $45.22 and a two-hundred day simple moving average of $44.69. PTC Therapeutics, Inc. has a one year low of $25.01 and a one year high of $55.58.

PTC Therapeutics (NASDAQ:PTCT – Get Rating) last released its quarterly earnings results on Tuesday, February 21st. The biopharmaceutical company reported ($2.35) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.39). The business had revenue of $167.41 million for the quarter, compared to analyst estimates of $183.07 million. The business’s revenue was up 1.3% on a year-over-year basis. During the same period last year, the firm posted ($2.03) earnings per share. Equities research analysts expect that PTC Therapeutics, Inc. will post -4.56 earnings per share for the current year.

About PTC Therapeutics

(Get Rating)

PTC Therapeutics, Inc is a biopharmaceutical company. It engages in discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.